anti-malarial program (Daiichi Sankyo/Medicines for Malaria Venture/Eisai/Millennium Pharmaceuticals)

N/A

Report date: 2025/03/17 20:00:36
NME

Base Information

Drug Nameanti-malarial program (Daiichi Sankyo/Medicines for Malaria Venture/Eisai/Millennium Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAcetate-CoA Ligase modulatorsProtein kinase PfCLK3 modulators
TargetsProtein kinase PfCLK3Acetate-CoA Ligase
Therapy Area/IndicationsMalaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDaiichi Sankyo IncMillennium Pharmaceuticals IncEisai Co Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsMalaria

Other Information

ATC CodeN/A
Related LinksN/A